New drugs in gynecologic oncology
- 1 September 1996
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 8 (5) , 408-414
- https://doi.org/10.1097/00001622-199609000-00013
Abstract
New agents with activity in recurrent epithelial ovarian cancer include the taxoids (paclitaxel and docetaxel), camptothecins (topotecan and irinotecan), gemcitabine, and oxaliplatin. In front-line therapy, the Gynecologic Oncology Group has shown that paclitaxel prolongs survival. In recurrent squamous carcinoma of the cervix, irinotecan has an objective response rate of 15%-24%. Both paclitaxel and docetaxel also show modest activity. Of these new agents, only paclitaxel has been evaluated in carcinoma of the endometrium, reporting a response rate of 35%.Keywords
This publication has 0 references indexed in Scilit: